EU Parliament Views Drug Industry vs Health Policy

8 October 1995

The European pharmaceutical industry's future should be seen in the framework of public health rather than as a purely industrial matter, to judge from the views expressed at a European Parliament hearing on the subject in Brussels last month.

Chairing the meeting was Irene Soltwedel-Schafer, rapporteur for the Parliament on the European Commission's 1994 communication on the outlines of an industrial policy for the pharmaceutical sector. Her principal question to the industry speakers was: "is the pharmaceutical industry prepared to commit itself to be guided in its research into and production of medicines by the Council of Europe' Bioethics Convention?"

Other Members of the European Parliament posed wide-ranging questions to the Commission and to drug industry speakers on employment, costs, orphan drugs and the reliability of the data on which the Commission had based its policy document. MEP Alma Metten suggested that the Commission depended too much on the industry for its data and for its arguments. However, with only around five minutes each to make their presentations to the hearing, there was little opportunity for a great deal of detail. Indeed, some questions, such as the important issue of employment within the pharmaceutical sector, did not get a hearing.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight